BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
IVDs on the rise
Radiopharmaceuticals
Science '22 in Review
Top Biopharma Trends of 2022
Top Med-tech Trends of 2022
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, October 1, 2023
See today's BioWorld
Home
» Zai Lab nabs $761M via secondary listing in Hong Kong
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Zai Lab nabs $761M via secondary listing in Hong Kong
Sep. 28, 2020
By
David Ho
No Comments
HONG KONG – U.S. listed Chinese biotech company Zai Lab Ltd. has raised $761 million in its secondary listing on the Hong Kong Stock Exchange.
BioWorld
Financings
Cancer
IPO
Asia-Pacific
